Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00051909
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Must have a clinical diagnosis of Alzheimer's Disease
- Must be at least 50 years of age
- Must fluently read and speak English
- Must have a reliable caregiver
Exclusion Criteria
- Has serious health problems other than Alzheimer's Disease
- Cannot swallow whole pills
- Has had a menstrual period in the last two years
- Takes insulin for diabetes
- Has taken Aricept, Reminyl, or Exelon in the last 5 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does LY451395 target in Alzheimer's disease pathophysiology?
How does LY451395 compare to cholinesterase inhibitors like Aricept in Alzheimer's treatment outcomes?
Which biomarkers correlate with LY451395 efficacy in early-stage Alzheimer's clinical trials?
What adverse events were observed in LY451395 phase 2 trials and how were they managed?
How does LY451395's mechanism relate to other anti-amyloid therapies in Alzheimer's development pipelines?